If it is that simple, it makes me feel a lot better. Basically BPO (based on one experienced patent attorney) wants to challenge SLA's IP over Bioeffectives.
For what its worth... its a very long shot. And screams 'desperation' if that is indeed what they are going for.
I mean they already had a chance to look at the patents during DD and signed off on those... Goodluck to BPO if that is the case. They'll need it!
- Forums
- ASX - By Stock
- Ann: Dispute with Solagran Limited
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)